Get the Stockscreener App
1.01
8.11%
-0.10
Tscan Therapeutics Inc stock is traded at $1.01, with a volume of 485.14K.
It is down -8.11% in the last 24 hours and down -4.67% over the past month.
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
See More
Previous Close:
$1.11
Open:
$1.08
24h Volume:
485.14K
Relative Volume:
0.58
Market Cap:
$66.33M
Revenue:
$10.33M
Net Income/Loss:
$-129.77M
P/E Ratio:
-1.0101
EPS:
-0.9999
Net Cash Flow:
$-140.33M
1W Performance:
-19.05%
1M Performance:
-4.67%
6M Performance:
-7.27%
1Y Performance:
-22.14%
1-Day Range:
$1.01
$1.10
1-Week Range:
$1.01
$1.31
52-Week Range:
$0.8824
$2.57
Tscan Therapeutics Inc Stock (TCRX) Company Profile
Name
Tscan Therapeutics Inc
Sector
Industry
Phone
857-399-9500
Address
830 WINTER STREET, WALTHAM
Compare TCRX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TCRX
Tscan Therapeutics Inc
|
1.015 | 75.81M | 10.33M | -129.77M | -140.33M | -0.9999 |
VRTX
Vertex Pharmaceuticals Inc
|
439.74 | 114.99B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
697.83 | 75.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.96 | 49.92B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
289.92 | 38.92B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
142.43 | 31.88B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tscan Therapeutics Inc Stock (TCRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-14-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-16-24 | Initiated | BTIG Research | Buy |
| May-13-24 | Initiated | Needham | Buy |
| Jun-22-23 | Initiated | Wedbush | Outperform |
Tscan Therapeutics Inc Stock (TCRX) Latest News
TradingKey - TradingKey
TCRX SEC FilingsTscan Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
The fundamentals driving TScan Therapeutics (TCRX) everyone should understand (Under Pressure) 2026-05-08 - newser.com
Wedbush Maintains TScan Therapeutics(TCRX.US) With Buy Rating, Maintains Target Price $5 - Moomoo
TScan Therapeutics, Inc. (TCRX) reports Q1 loss, lags revenue estimates - MSN
Buy Rating Reiterated on TSC-101 Ahead of Key ALLOHA Readouts and Pipeline Expansion; $6 Price Target Maintained - TipRanks
TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - Black Hills Pioneer
TScan Therapeutics, Inc. 2026 Q1 10-Q Report: Financials, Risk Factors, and Forward-Looking Statements - Minichart
TScan Therapeutics Announces Q1 2026 Financial Results, Phase 3 TSC-101 Trial Launch, and Pipeline Updates - Minichart
TScan Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
TScan Therapeutics, Inc. 1Q 2026: Revenue $982K, EPS $(0.22) — 10-Q Summary - TradingView
TScan Therapeutics Reports $175.3 Million in Cash Reserves, Funding Operations Into Second Half of 2028 - geneonline.com
TScan Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
TScan Therapeutics (NASDAQ: TCRX) narrows Q1 2026 loss as R&D declines and cash runway extends - Stock Titan
TScan Therapeutics (NASDAQ: TCRX) narrows Q1 loss, plans Phase 3 - Stock Titan
TScan lines up Phase 3 blood cancer study as patient data nears - Stock Titan
Is TScan Therapeutics (TCRX) stock worth taking a position in - newser.com
TScan Therapeutics (TCRX) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
TScan Therapeutics Announces Upcoming Presentation at the - GlobeNewswire
TScan brings post-transplant cancer relapse research to Boston meeting - Stock Titan
TCRX Financials: Income Statement, Balance Sheet & Cash Flow | Tscan Therapeutics, Inc. - Stock Titan
Is institutional money buying TScan Therapeutics (TCRX) stock | Q4 2025: Profit Exceeds ViewsEarnings Analysis - newser.com
LifeSci Capital Maintains TScan Therapeutics(TCRX.US) With Buy Rating, Maintains Target Price $6 - Moomoo
TScan Therapeutics (NASDAQ: TCRX) seeks big boost in authorized shares at 2026 meeting - Stock Titan
Needham Maintains TScan Therapeutics(TCRX.US) With Buy Rating, Maintains Target Price $6 - Moomoo
TCRX: TCR T cell therapy shows >50% relapse reduction in AML/MDS, pivotal trial starts mid-2024 - TradingView
TCRX: TCR T cell therapy halves relapse rates in AML/MDS, with pivotal trial and expansion planned - TradingView
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
TScan Therapeutics, Inc. (NASDAQ:TCRX) Given Average Rating of "Hold" by Analysts - MarketBeat
H.C. Wainwright reiterates Buy on Tscan stock, $7 target By Investing.com - Investing.com Australia
H.C. Wainwright reiterates Buy on Tscan stock, $7 target - Investing.com
TScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference - Sahm
TScan Therapeutics (NASDAQ: TCRX) seeks approval to double authorized shares to 600M - Stock Titan
TScan Therapeutics (NASDAQ:TCRX) Shares Up 3%Here's What Happened - MarketBeat
TScan Therapeutics (NASDAQ:TCRX) Shares Up 3% – Here’s What Happened - Defense World
Market Recap: Will TScan Therapeutics Inc stock benefit from M A2026 Technical Overview & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Will TScan Therapeutics (TCRX) Stock Recover Soon | Price at $1.06, Up 5.45%Technical Analysis - newser.com
TCRX Stock Analysis: TScan Therapeutics Inc. Biotech at $1 Level Following Small Daily Dip - Xã Thanh Hà
TScan Therapeutics Consolidates Finance Leadership After Officer Resignation - TipRanks
TScan Therapeutics announces resignation of vice president of finance - Investing.com UK
TScan Therapeutics announces resignation of vice president of finance By Investing.com - Investing.com Australia
TScan Therapeutics (TCRX) CFO adds principal accounting officer role after VP finance resignation - Stock Titan
TCRX Technical Analysis & Stock Price Forecast - Intellectia AI
TCRX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Strong analyst sentiment on TScan Therapeutics (TCRX) amid ongoing momentum in cell therapy space - MSN
Strong Analyst Sentiment on TScan Therapeutics (TCRX) Amid Ongoing Momentum in Cell Therapy Space - Yahoo Finance
Earnings Risk: Will TScan Therapeutics Inc stock benefit from M A2026 Price Targets & Weekly High Potential Stock Alerts - baoquankhu1.vn
Top 10 Stocks Under $5 That Could Triple - Insider Monkey
Aug Catalysts: Will TScan Therapeutics Inc outperform its industry peersQuarterly Portfolio Summary & Safe Entry Trade Reports - baoquankhu1.vn
Retail Trends: What is the implied volatility of TScan Therapeutics Inc2026 Price Targets & Scalable Portfolio Growth Methods - baoquankhu1.vn
Tscan Therapeutics Inc Stock (TCRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Tscan Therapeutics Inc Stock (TCRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lynx1 Capital Management LP | 10% Owner |
Dec 22 '25 |
Buy |
0.90 |
75,500 |
67,950 |
8,012,916 |
| Lynx1 Capital Management LP | 10% Owner |
Dec 23 '25 |
Buy |
0.90 |
6,232 |
5,602 |
8,019,148 |
| Lynx1 Capital Management LP | 10% Owner |
May 19 '25 |
Buy |
1.20 |
1,388,794 |
1,666,553 |
6,746,141 |
| Lynx1 Capital Management LP | 10% Owner |
May 20 '25 |
Buy |
1.20 |
1,200,000 |
1,440,000 |
7,946,141 |
0.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):